2nd Quarter - Report

FEROX STRATEGIES for VIATRIS INC

Period 2nd Quarter 2026 Filed Jul 20, 2026 Signed by Cristina Antelo

Official filing
Firm
FEROX STRATEGIES
Client
VIATRIS INC
Income
$70,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).

LobbyistCovered position, as disclosed
CRISTINA ANTELO —
DEBRA DIXON —
ZACHARY BENJAMIN FRIEND —
MICHAEL TAGGART —
MARK WILLIAMS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 1071 (119th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines.

LobbyistCovered position, as disclosed
MARK WILLIAMS —

Contacted: Commerce, Dept of (DOC); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.